Pfizer Gets Expanded European OK for Hympavzi Hemophilia Drug

Published: 2026-05-13 07:11:21 ET PFE

Published on 05/13/2026 at 07:11 am EDT

By Colin Kellaher

Pfizer has won expanded European Commission approval of its Hympavzi hemophilia drug for two patient populations.

Pfizer on Wednesday said the green light covers patients ages 12 and older weighing at least 35 kilograms with hemophilia A with FVIII inhibitors or hemophilia B with FIX inhibitors.

The New York drugmaker said inhibitors limit treatment options for people living with hemophilia and are associated with an increased risk of uncontrolled bleeding.

Pfizer said Hympavzi is now the only once-weekly subcutaneous treatment approved in the European Union for people living with hemophilia A or B with or without inhibitors.

Write to Colin Kellaher at [email protected]

(END) Dow Jones Newswires

05-13-26 0711ET